AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04012424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 400mg starch
Description: patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
Study NCT04365478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy
Description: rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
Study NCT04365478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
Study NCT03601741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Antimicrobial Stethoscope Diaphragm Cover
Description: Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
Study NCT03601741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Stethoscopes
Description: Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
Study NCT02719834 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
Study NCT02719834 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
Study NCT03373461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 5, 25, 100 mg capsles
Study NCT03373461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LNP023
Study NCT03246841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetic testing
Description: A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
Study NCT00667797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol HCl
Description: Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
Study NCT00667797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol Sulfate
Description: Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
Study NCT04182438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low potassium content vegetables
Description: use low-potassium content vegetables
Study NCT02846870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visually enhanced prostate cancer educational presentation
Description: Receive visually enhanced prostate cancer educational presentation
Study NCT02846870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard prostate cancer education presentation
Description: Receive standard prostate cancer education presentation
Study NCT00323037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol controlled release
Description: Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
Study NCT00323037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol immediate release
Description: Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
Study NCT04813913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV
Description: Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
Study NCT03152994 — intervention group
Intervention type: OTHER
Intervention: Checking fasting blood glucose(FBG)
Description: This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
Study NCT03769194 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15
Description: a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
Study NCT03769194 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: PBS (Phosphate Buffered Saline)
Study NCT02652598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Study NCT04508114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Index
Description: The participant will be informed the ATP testing result and explanation in pretest.
Study NCT01507714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preventive transobturator tension free vaginal tape
Description: during the vaginal wall repair surgery, a TVT-O procedure will be done
Study NCT03766893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy maintenance addiction care
Description: Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
Study NCT00203905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
Study NCT00203905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Hydroxyurea-[FHX]
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
Study NCT02950935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Study NCT02950935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Study NCT03854240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic block (Group C) and modified block (Group M) groups
Description: Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
Study NCT02348320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized polyepitope DNA vaccine
Study NCT01368211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Mirasol-treated Platelets Transfusion
Description: 2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of >32%~* Cell count > 800x103/µL
Study NCT01368211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Untreated Platelets Transfusion
Description: 2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of >32%~* Cell count > 800x103/µL
Study NCT03087331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reviews, assessment, recommendations, education.
Study NCT04028947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
Description: Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
Study NCT04477733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Injection
Description: Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
Study NCT04477733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
Study NCT03385616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gala Airway Treatment System
Description: The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
Study NCT04297475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-modal photoacoustic/ultrasonic (PA/US) imaging system
Description: The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
Study NCT03146728 — intervention group
Intervention type: OTHER
Intervention: exercise
Description: energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
Study NCT04234503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethics Quarter
Description: In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory.
Study NCT04206709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic effort
Description: Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
Study NCT03338569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Continuous infusion of vitamin C
Study NCT03338569 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo designed to mimic intervention
Study NCT04344535 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma
Description: 450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally > 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
Study NCT04344535 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Donor Plasma
Description: 450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
Study NCT03729622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low FODMAP Diet
Description: Both arms will receive the intervention but at different time points.
Study NCT03729622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Both arms will receive the intervention but at different time points.
Study NCT04206709 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive pedaling
Description: 20 minutes passive pedaling by upper limbs.
Study NCT02450097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Caloric restriction
Study NCT02483598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
Study NCT01029613 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: sc. inj. Humira 40 mg every other week from week 0 to 52
Study NCT02483598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
Study NCT02483598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone and Grapefruit Juice
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Study NCT00866333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets
Study NCT00946894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: Total thyroidectomy
Study NCT00946894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dunhill operation
Description: Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
Study NCT00946894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subtotal thyroidectomy
Description: Bilateral subtotal thyroidectomy
Study NCT02441751 — intervention group
Intervention type: PROCEDURE
Intervention: intra-operative blood loss
Description: surgery in the urology and orthopedics
Study NCT01309984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lusedra
Description: Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
Study NCT01309984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
Study NCT01528137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: talactoferrin
Description: Given PO
Study NCT01528137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01160835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplastyinstruments
Description: Quadriceps-sparing arthrotomy with side-cutting instruments
Study NCT01160835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplastyinstruments
Description: Quadriceps-sparing arthrotomy with side-cutting instruments
Study NCT01388504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
Study NCT01388504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
Study NCT04015778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg Q2W or 360mg Q3W
Study NCT04015778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5, d1 every three weeks
Study NCT04015778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 135 mg/m2, d1, 8
Study NCT01916902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor- Delayed Administration
Description: Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Study NCT01916902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor- Immediate Administration
Description: Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Study NCT01916902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Study NCT01564641 — intervention group
Intervention type: DEVICE
Intervention: iDuo G2
Description: single comparator
Study NCT03667027 — intervention group
Intervention type: DEVICE
Intervention: Respiratory support
Description: Mechanical ventilation or extracorporeal life support
Study NCT01770067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CITA-RNPT
Study NCT01770067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of infected CIED
Study NCT03558841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with the THERA-Trainer Lyra
Description: Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
Study NCT03558841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
Study NCT03558841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
Study NCT02245113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diets
Description: Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
Study NCT02483598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone and Grapefruit Juice
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Study NCT02886169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal with Sacha Inchi
Description: Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
Study NCT02886169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high saturated fat meal
Description: Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
Study NCT02970305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
Study NCT02970305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth
Study NCT02207036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook intervention
Description: 90 days of Facebook messaging, weekly Ask the Doctor sessions
Study NCT02207036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokefree.gov
Description: referral to the NCI Smokefree.gov website
Study NCT00270647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
Study NCT00270647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
Study NCT00270647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))